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Successful treatment of head lice infestations may be hampered by limited ovicidal efficacy of current treatments 1 , increasing resistance to commonly used treatments 2 , and poor adherence to 2-application treatment regimens.
Abametapir lotion, 0.74%, contains the active ingredient abametapir, a compound with a new mode of action 3 being developed for the single-application treatment of head lice infestation.
The objective of the current studies was to evaluate the efficacy of a single 10 minute application of abametapir lotion, 0.74% for the treatment of head lice infestation in subjects 6 months of age and older.
Two randomized, double-blind, vehicle-controlled, parallel-group, multi-center studies were conducted in subjects aged ≥ 6 months with active head lice infestations along with household members with ≥ 1 live louse.
Households were equally randomized to receive abametapir lotion, 0.74% or vehicle.
Product was applied to dry hair for 10 minutes and rinsed with water. No nit combing was performed. Following treatment, subjects were inspected for live lice on days 1, 7, and 14.
Treatment success was defined as being louse-free at all post-baseline visits through day 14.
Enrollment included a total of 704 subjects with comparable demographics in each study. For all subjects treatment success was 88.2% (165/187) and 81.0% (132/163) with abametapir lotion, 0.74% for the two studies, respectively, compared with 62.0% (119/192) and 60.5% (98/162) for the vehicle groups (both P<.001) (Table1).
The most common treatment emergent adverse events were erythema, rash, and skin burning sensation ( Table 2) .
A single, 10-minute application of abametapir lotion, 0.74% was effective in treating active head lice infestation within 14 days in subjects 6 months or older.
In this study, the most common adverse events were erythema, rash, and skin burning (range 2.6% to 4.0%) and there were no serious adverse events. 
